TSCAN THERAPEUTICS, INC. Long-Term Debt, Maturity, Year Five
TSCAN THERAPEUTICS, INC. (TCRX) had Long-Term Debt, Maturity, Year Five of $12.19 million as of 2025-09-30, per its 10-Q filed 2025-11-12.
Financial Statements › Notes › Commitment and Contingencies › Long-Term Debt, Fiscal Year Maturity › Long-Term Debt, Maturity, Year Four and Five
us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive · last filed 2025-11-12
- 2025-09-30: Long-Term Debt, Maturity, Year Five $12.19M.
- 2025-06-30: Long-Term Debt, Maturity, Year Five $12.19M.
- 2025-03-31: Long-Term Debt, Maturity, Year Five $12.19M.
- 2024-12-31: Long-Term Debt, Maturity, Year Five $12.19M.
| Period end | Long-Term Debt, Maturity, Year Five |
|---|---|
| 2025-09-30 | $12.19M 10-Q · filed 2025-11-12 |
| 2025-06-30 | $12.19M 10-Q · filed 2025-08-12 |
| 2025-03-31 | $12.19M 10-Q · filed 2025-05-06 |
| 2024-12-31 | $12.19M 10-K · filed 2025-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| VivoSim Labs, INC. (VIVS) | United States | $0.003B |